Skip to main content
Erschienen in: Reactions Weekly 1/2023

01.08.2023 | Case report

Nusinersen/risdiplam

Lack of efficacy: 3 case reports

Erschienen in: Reactions Weekly | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Blaschek A, et al. Newborn Screening for SMA - Can a Wait-and-See Strategy be Responsibly Justified in Patients With Four SMN2 Copies?. Journal of Neuromuscular Diseases 9: 597-605, No. 5, Jan 2022. Available from: URL: http://doi.org/10.3233/JND-221510 Blaschek A, et al. Newborn Screening for SMA - Can a Wait-and-See Strategy be Responsibly Justified in Patients With Four SMN2 Copies?. Journal of Neuromuscular Diseases 9: 597-605, No. 5, Jan 2022. Available from: URL: http://​doi.​org/​10.​3233/​JND-221510
Metadaten
Titel
Nusinersen/risdiplam
Lack of efficacy: 3 case reports
Publikationsdatum
01.08.2023
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2023
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-023-45334-y

Weitere Artikel der Ausgabe 1/2023

Reactions Weekly 1/2023 Zur Ausgabe

Case report

Multiple drugs

Case report

Multiple drugs

Case report

Multiple drugs

Case report

Linezolid

Case report

Sunitinib